A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of the Efficacy and Safety of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Plaque Psoriasis.

Trial Profile

A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of the Efficacy and Safety of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Plaque Psoriasis.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 26 Aug 2016

At a glance

  • Drugs Piclidenoson (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Can-Fite BioPharma
  • Most Recent Events

    • 26 Aug 2016 Data from this trial were published in August 2016 issue of Journal of Drugs in Dermatology , according to a Can-Fite Biopharma media release.
    • 08 Mar 2016 Results presented at the 74th Annual Meeting of the American Academy of Dermatology
    • 03 Mar 2016 According to Can-Fite BioPharma media release, results will be presented at the American Academy of Dermatology's 74th Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top